Merck & Co., Inc.

NYSE: MRK
$78.78
+$0.66 (+0.8%)
Closing price July 2, 2020
Merck shares jumped on Tuesday after the company announced that it has made deals to develop drugs in the fight against COVID-19.
Merck and Pfizer reported their most recent quarterly results before the opening bell Tuesday. Although markets appear to be recovering, investors were not thrilled about this quarter for these two...
Pharmaceutical giants Merck and Pfizer are expected to report their most recent quarterly results before the opening bell Tuesday.
The April 15 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Over one-third of the Dow Jones industrial average components are scheduled to report their latest quarterly reports this week. Here's what to expect.
The March 31 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
24/7 Wall St. wanted to see which companies have the best chance at not having to lower their dividends at all and those that almost certainly will retain much of their current dividends in a...
The February 28 short interest data have been compared with the previous figures, and short interest in these top pharmaceutical stocks decreased.
The February 14 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
With billions of dollars flowing in, it has become impossible to ignore the ESG trend. These 15 top ESG stocks appear to be undervalued against the performance of the broader markets.
The January 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Thursday's top analyst upgrades, downgrades and initiations included AbbVie, Biogen, Boeing, Etsy, Gilead Sciences, GoPro, Micron Technology, Newmont, Peloton Interactive, Pfizer, Valero Energy and...
Merck finds itself in a position of being an acquirer of sorts at the same time it wants to spin out part of its operations. Executing this effort may create some operational uncertainty inside of...
Merck reported fourth-quarter financial results before the markets opened on Wednesday that were essentially in line with expectations, yet shares retreated in early trading.
Merck is scheduled to release its fourth-quarter financial results before the markets open on Wednesday. Analysts are looking for year-over-year growth on the top and bottom lines.